At the news
? NEUTRALIMPACT 4/10 CLUSTER filed Aug 20, 2026 at 17:30 ET
Four Rocket Pharmaceuticals insiders, including CEO Gaurav Shah and COO Christopher Stevens, sold a total of $164K in open-market sales over the past week. This cluster comes just 10 days after Q2 earnings that showed a GAAP net income of $123.2M, driven by a $178.2M PRV sale, extended cash runway into Q2 2028, and positive Danon disease Phase 2 data. However, sales are modest relative to the $401M market cap (0.04%), and the post-earnings timing aligns with a typical blackout-window opening, reducing informational significance per academic literature on cluster sells.
- CEO Gaurav Shah sold 2,293 shares at $3.381 for ~$8K on 2026-08-18.
- COO Christopher Stevens sold 36.7K shares at $3.50 for $128K on 2026-08-11.
- Total insider sales of $164K represent ~0.04% of the $401M market cap, below the 0.1% materiality threshold.
- Cluster occurred 10 days after a bullish Q2 earnings 8-K (GAAP net income $123.2M vs. $68.9M loss YoY, cash runway extended to Q2 2028).
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access